FIELD: chemistry.
SUBSTANCE: invention is related to a crystalline form of X {4-[(1R, 3S)-3-((R)-1-naphthalene-1-ilethylamino) cyclopentyl] phenoxy} acetic acid, which can be used for treating, relieving or preventing the physiological disorders or diseases associated with disturbed activity of CaSR, such as hyperparathyroidism. This form has x-ray powder diffraction pattern, which demonstrates characteristic peaks expressed in 2θ, equal to approximately 8.0, 11.3, 11.4, 15.0, 18.2 and/or 21.5 degrees (±0.05 degrees) (underlined is the primary).
EFFECT: invention is also related to a pharmaceutical compound containing the crystalline form of X, and methods for preparing it.
19 cl, 10 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW POLYMORPHIC FORM OF A CALCIEMETRIC COMPOUND | 2011 |
|
RU2599789C2 |
| NOVEL CYCLIC HYDROCARBON COMPOUNDS FOR TREATMENT OF DISEASES | 2008 |
|
RU2524949C2 |
| 7-[3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYL-PENT-1-ENYL)-CYCLOPENTYL]-N-ETHYL-HEPT-5-ENEAMIDE (BIMATOPROST) IN CRYSTALLINE FORM II, METHODS OF THEREOF OBTAINING AND METHODS FOR APPLICATION THEREOF | 2010 |
|
RU2577546C2 |
| NOVEL CRYSTALLINE FORM OF TRIAZOLO(4,5-d)PYRIMIDINE | 2005 |
|
RU2418802C2 |
| SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-cd]INDOL-6-ONE | 2011 |
|
RU2570198C2 |
| OBTAINING CRYSTALLINE ANTIBIOTIC | 2006 |
|
RU2418806C2 |
| NEW CRYSTAL AND AMORPHOUS FORM OF TRYAZOL[4,5-d] PYRIMIDINE | 2001 |
|
RU2325391C2 |
| POLYMORPHIC FORMS | 2014 |
|
RU2670978C9 |
| NEW TETRACYCLIC CYSTEIN PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF AND APPLICATION THEREOF | 2007 |
|
RU2481349C2 |
| COMBINATIONS OF ALPHA-2-DELTA-LIGAND WITH SELECTIVE CYCLOIXYGENASE-2 INHIBITOR | 2003 |
|
RU2286151C2 |
